Key Insights

Highlights

Success Rate

75% trial completion

Treatment Research

5 treatments under study, led by Secukinumab

Research Leaders

5 sponsors active, led by Mayne Pharma International Pty Ltd

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

75.0%

-11.6% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed with results

Key Signals

2 with results75% success

Data Visualizations

Phase Distribution

3Total
Phase 2 (2)
Phase 3 (1)

Trial Status

Completed3
Terminated1

Trial Success Rate

75.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT01222000Phase 3CompletedPrimary

Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous

NCT03738800Phase 2TerminatedPrimary

A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

NCT03041038Phase 2Completed

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

NCT00001292Completed

Study of Scaling Disorders and Other Inherited Skin Diseases

Showing all 4 trials

Research Network

Common Treatments

  • Secukinumab1
  • Cd5789 Cream 100 Μgg1
  • Cd5789 Cream 200 Μgg1
  • Cd5789 Cream Vehicle1
  • Apply Veregen 10 On A Randomized Area And The Moisturizing Cream Of The Other Side1

Active Sponsors

  • Mayne Pharma International Pty Ltd1
  • National Cancer Institute (NCI)1
  • Centre Hospitalier Universitaire de Nice1
  • Northwestern University1
  • Icahn School of Medicine at Mount Sinai1

Top Investigators

Related Conditions

  • Ichthyosis1
  • Keratosis Follicularis1
  • Autosomal Recessive Congenital Ichthyosis1
  • Congenital Ichthyosiform Erythroderma1
  • Genetic Skin Disease1

Activity Timeline